AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS

AtriCure (NASDAQ:ATRC) issued its earnings results on Wednesday. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.10, Zacks reports. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The business had revenue of $134.27 million for the quarter, compared to analyst estimates of $131.25 million. During the same period last year, the company posted ($0.17) EPS. The business’s quarterly revenue was up 15.8% on a year-over-year basis. AtriCure updated its FY 2025 guidance to -0.260–0.230 EPS.

AtriCure Stock Performance

AtriCure stock opened at $35.44 on Thursday. The firm has a market capitalization of $1.76 billion, a PE ratio of -46.03 and a beta of 1.59. AtriCure has a one year low of $28.29 and a one year high of $43.11. The stock’s 50 day moving average price is $36.12 and its 200 day moving average price is $33.93. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

Insider Activity

In other news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total transaction of $91,450.00. Following the sale, the insider owned 71,872 shares in the company, valued at $2,629,077.76. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Regina E. Groves sold 2,452 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the transaction, the director owned 33,715 shares of the company’s stock, valued at $1,241,386.30. This trade represents a 6.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 17,952 shares of company stock worth $655,633. Company insiders own 3.50% of the company’s stock.

Institutional Trading of AtriCure

Large investors have recently modified their holdings of the business. Captrust Financial Advisors increased its position in shares of AtriCure by 8.9% during the second quarter. Captrust Financial Advisors now owns 7,299 shares of the medical device company’s stock worth $239,000 after acquiring an additional 598 shares during the last quarter. California State Teachers Retirement System grew its stake in AtriCure by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company’s stock valued at $1,475,000 after purchasing an additional 691 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in AtriCure by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,370 shares of the medical device company’s stock worth $799,000 after purchasing an additional 765 shares during the last quarter. AQR Capital Management LLC increased its holdings in AtriCure by 1.0% during the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after purchasing an additional 837 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at approximately $37,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ATRC. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Thursday. Wall Street Zen raised shares of AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, October 8th. BTIG Research set a $54.00 price objective on shares of AtriCure in a research note on Wednesday, July 30th. Finally, Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.89.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.